Skip the wait and schedule your appointments online or through MyChart.

Research & Innovation

Clinical Trials

Clinical Trials

Arcutis ARQ-151-315 Pediatric Atopic Dermatitis

A 4-Week, Double Blind, Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis (ARQ-151-315)

Physician & Study Coordinator


Andrew Krakowski, MD

Study Coordinators

Heather Herbold



This study is being done to evaluate the safety and efficacy of ARQ-151 cream in children with mild to moderate eczema (atopic dermatitis) after application once every day for a month.


Eligibility Criteria
  • Informed consent by parent(s) or legal guardian as required by local laws
  • Males and females, ages 2 to 5 years old at time of signing Informed Consent (Screening) and at Baseline (Day 1)
  • Diagnosed with atopic dermatitis for at least 6 weeks, as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening
  • In good health as judged by the Investigator